MNMD
Price
$8.87
Change
-$0.01 (-0.11%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
670.91M
26 days until earnings call
ZVRA
Price
$12.06
Change
-$0.60 (-4.74%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
659.98M
31 days until earnings call
Interact to see
Advertisement

MNMD vs ZVRA

Header iconMNMD vs ZVRA Comparison
Open Charts MNMD vs ZVRABanner chart's image
Mind Medicine (MindMed)
Price$8.87
Change-$0.01 (-0.11%)
Volume$12.67K
Capitalization670.91M
Zevra Therapeutics
Price$12.06
Change-$0.60 (-4.74%)
Volume$33.03K
Capitalization659.98M
MNMD vs ZVRA Comparison Chart in %
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. ZVRA commentary
Jul 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a Hold and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 19, 2025
Stock price -- (MNMD: $8.88 vs. ZVRA: $12.66)
Brand notoriety: MNMD and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 86% vs. ZVRA: 162%
Market capitalization -- MNMD: $670.91M vs. ZVRA: $659.98M
MNMD [@Biotechnology] is valued at $670.91M. ZVRA’s [@Biotechnology] market capitalization is $659.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $293.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than MNMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 6 TA indicator(s) are bullish while ZVRA’s TA Score has 5 bullish TA indicator(s).

  • MNMD’s TA Score: 6 bullish, 5 bearish.
  • ZVRA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both MNMD and ZVRA are a good buy in the short-term.

Price Growth

MNMD (@Biotechnology) experienced а +9.63% price change this week, while ZVRA (@Biotechnology) price change was +5.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($671M) and ZVRA($660M) have the same market capitalization . ZVRA YTD gains are higher at: 51.799 vs. MNMD (27.586). ZVRA has higher annual earnings (EBITDA): -60.3M vs. MNMD (-75.18M). MNMD has more cash in the bank: 212M vs. ZVRA (62.6M). MNMD has less debt than ZVRA: MNMD (22M) vs ZVRA (61.8M). ZVRA has higher revenues than MNMD: ZVRA (40.6M) vs MNMD (0).
MNMDZVRAMNMD / ZVRA
Capitalization671M660M102%
EBITDA-75.18M-60.3M125%
Gain YTD27.58651.79953%
P/E RatioN/AN/A-
Revenue040.6M-
Total Cash212M62.6M339%
Total Debt22M61.8M36%
FUNDAMENTALS RATINGS
MNMD vs ZVRA: Fundamental Ratings
MNMD
ZVRA
OUTLOOK RATING
1..100
528
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
85
Overvalued
PROFIT vs RISK RATING
1..100
9462
SMR RATING
1..100
9799
PRICE GROWTH RATING
1..100
3936
P/E GROWTH RATING
1..100
10023
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (35) in the null industry is somewhat better than the same rating for ZVRA (85). This means that MNMD’s stock grew somewhat faster than ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (62) in the null industry is in the same range as MNMD (94). This means that ZVRA’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's SMR Rating (97) in the null industry is in the same range as ZVRA (99). This means that MNMD’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (36) in the null industry is in the same range as MNMD (39). This means that ZVRA’s stock grew similarly to MNMD’s over the last 12 months.

ZVRA's P/E Growth Rating (23) in the null industry is significantly better than the same rating for MNMD (100). This means that ZVRA’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDZVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
MACD
ODDS (%)
Bullish Trend 1 day ago
89%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 5 days ago
81%
Declines
ODDS (%)
Bearish Trend 19 days ago
86%
Bearish Trend 19 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ASEFX15.270.20
+1.33%
Nuveen Small Cap Select R6
NMFAX15.620.09
+0.58%
Nationwide BNY Mellon Dyn US Core A
FSZZX10.380.06
+0.58%
Fidelity Advisor Sustainable EM Eq Z
JLCVX73.790.37
+0.50%
JHancock Fundamental Large Cap Core R5
VREMX8.28-0.01
-0.12%
Virtus SGA Emerging Markets Equity R6

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+3.50%
ATAI - MNMD
52%
Loosely correlated
+3.33%
BEAM - MNMD
51%
Loosely correlated
+1.89%
OCUL - MNMD
51%
Loosely correlated
+1.16%
EYPT - MNMD
50%
Loosely correlated
+2.39%
RXRX - MNMD
50%
Loosely correlated
+5.75%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with ATXS. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+2.76%
ATXS - ZVRA
37%
Loosely correlated
N/A
CRNX - ZVRA
36%
Loosely correlated
+3.51%
DNTH - ZVRA
36%
Loosely correlated
+2.57%
MNMD - ZVRA
35%
Loosely correlated
+3.50%
EYPT - ZVRA
34%
Loosely correlated
+2.39%
More